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Bone is constantly being molded and shaped by the action of osteoclasts and 
osteoblasts. A proper equilibrium between both cell types metabolic activities is 
required to ensure an adequate skeletal tissue structure, and it involves resorption of old 
bone and formation of new bone tissue. It is reported that treatment with antiepileptic 
drugs (AEDs) can elicit alterations in skeletal structure, in particular in bone mineral 
density. Nevertheless, the knowledge regarding the effects of AEDs on bone cells are 
still scarce, particularly on osteoclastic behaviour. In this context, the aim of this study 
was to investigate the effects of five different AEDs on human osteoclastic cells. 
Osteoclastic cell cultures were established from precursor cells isolated from human 
peripheral blood, and were maintained in the absence (control) or in the presence of 10
-
8
-10
-4
 M of different AEDs (valproate, carbamazepine, gabapentin, lamotrigine and 
topiramate). Cell cultures were characterized throughout a 21-day period for tartrate-
resistant acid phosphatase (TRAP) activity, number of TRAP+ multinucleated cells, 
presence of cells with actin rings and expressing vitronectin and calcitonin receptors, 
and apoptosis rate. Also, the involvement of several signaling pathways on the cellular 
response was addressed. 
All the tested drugs were able to affect osteoclastic cell development, although with 
different profiles on their osteoclastogenic modulation properties. Globally, the 
tendency was to inhibit the process. Furthermore, the signaling pathways involved in 
the process also seemed to be differentially affected by the AEDs, suggesting that the 
different drugs may affect osteoclastogenesis through different mechanisms. 
In conclusion, the present study showed that the different AEDs had the ability to 
negatively modulate the osteoclastogenesis process, shedding new light towards a better 
understanding of how these drugs can affect bone tissue. 
